WO2023131866 - BIOMARKERS FOR MYELODYSPLASTIC SYNDROME (MDS) AND METHODS OF USING THE SAME
National phase entry is expected:
Publication Number
WO/2023/131866
Publication Date
13.07.2023
International Application No.
PCT/IB2023/000007
International Filing Date
04.01.2023
Title **
[English]
BIOMARKERS FOR MYELODYSPLASTIC SYNDROME (MDS) AND METHODS OF USING THE SAME
[French]
BIOMARQUEURS POUR LE SYNDROME MYÉLODYSPLASIQUE (MDS) ET LEURS MÉTHODES D'UTILISATION
Applicants **
EISAI R&D MANAGEMENT CO., LTD.
Inventors
GUALBERTO, Antonio
SCHOLZ, Catherine
XIAO, Jianjun, Alan
PENUGONDA, Sudhir
Priority Data
63/266,455
05.01.2022
US
63/266,619
10.01.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2898 | |
| EPO | Filing, Examination, Granting | 15756 | |
| Japan | Filing, Examination, Granting | 2525 | |
| South Korea | Filing, Examination, Granting | 2750 | |
| USA | Filing, Examination, Granting | 10590 |
Total:
34,519
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
AJ/CJ ratio. Therapeutic uses and compositions are also disclosed.[French]
AJ/CJ du patient. Sont également divulguées ici des compositions et des utilisations thérapeutiques.